Drug Trial Radar · NCT07421869
SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Mar 4, 2029
Study completion Mar 4, 2029
Sponsor
- Lead sponsor
- Seoul National University Bundang HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to find out whether hypothyroidism caused by immune checkpoint inhibitors (ICIs) can recover after stopping the ICIs. The study also aims to identify factors that can help predict which patients will be able to stop taking thyroid hormone replacement. The main questions the study will answer are: * What percentage of patients recover normal thyroid function and can stop levothyroxine after stopping ICIs? * What clinical or laboratory factors can predict successful withdrawal of levothyroxine? Participants will: * Be adult cancer patients who developed hypothyroidism during ICI treatment and are currently taking levothyroxine * Have already stopped ICI therapy * Gradually reduce their levothyroxine dose every 3 months if their thyroid function remains normal * Stop levothyroxine if thyroid function remains normal at low doses (≤0.025 mg) * Be monitored with thyroid function tests and clinical symptoms at each visit
Conditions
- Hypothyroidism
Interventions
Levothyroxine taperingDrug
Participants will undergo a gradual dose reduction of levothyroxine according to a standardized tapering protocol. The levothyroxine dose will be reduced every 3 months based on thyroid function test results. If thyroid function remains stable, the dose will be decreased by 0.025 mg (±0.0125 mg). If thyroid function remains stable at a low dose (≤0.025 mg), levothyroxine will be discontinued.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who maintain discontinuation of levothyroxine for at least 6 monthsTime frame: Up to 6 months after levothyroxine discontinuation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Internal Medicine, Seoul National University Bundang Hospital
Seongnam-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.